Merck’s potential antiviral, molnupiravir, may generate $5 billion to $7 billion in sales through next year, company executives told analysts Thursday morning.
Merck’s potential antiviral, molnupiravir, may generate $5 billion to $7 billion in sales through next year, company executives told analysts Thursday morning.
Copyright © 2024 | WordPress Theme by MH Themes